Company Profile
Apogee Therapeutics Stock Price, News & Catalysts
- Ticker:
- APGE
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
134.59 USD (+0.03%)
Close
Last updated: August 17, 2026
5.93B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, APGE was little changed and closed at $134.59. No new same-company headline was identified in the current news window.
Company overview
Long-Acting I&I Biologics
Apogee Therapeutics develops optimized biologics for inflammatory and immunologic diseases. Its candidates are engineered for differentiated efficacy and extended dosing intervals across large chronic indications.
Zumilokibart
Zumilokibart is a long-acting antibody targeting IL-13 and is the company's lead program. Its extended half-life is intended to support dosing at intervals measured in months.
Atopic-Dermatitis Program
The APEX Phase 2 program evaluates induction and maintenance regimens of zumilokibart in moderate-to-severe atopic dermatitis to support Phase 3 dose selection.
Asthma and Eosinophilic Esophagitis
Following Phase 1b asthma results, Apogee is planning broader development of zumilokibart in asthma and eosinophilic esophagitis, treating the antibody as a pipeline-in-a-product.
Broader I&I Portfolio
The company is also building biologics for chronic obstructive pulmonary disease and other inflammatory conditions, seeking to improve the dosing and efficacy profiles of validated therapeutic targets.
Future catalysts
- Initiation of Phase 3 studies of zumilokibart in atopic dermatitis in 2026.
- Initiation of the ELEVATE Phase 2a study of zumilokibart in eosinophilic esophagitis in the second half of 2026.
- Interim data from the Phase 1b APG279 head-to-head study in atopic dermatitis in the second half of 2026.
- Initiation of the potentially registrational ASPIRE Phase 2b asthma study in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Apogee Therapeutics (APGE)?
Apogee Therapeutics (APGE) most recently closed at 134.59 USD, a +0.03% move versus the previous session.
What is the market cap of Apogee Therapeutics (APGE)?
Apogee Therapeutics currently has a market capitalization of 5.93B USD on BioPharmSignal.
What does Apogee Therapeutics do?
Long-Acting I&I Biologics Apogee Therapeutics develops optimized biologics for inflammatory and immunologic diseases. Its candidates are engineered for differentiated efficacy and extended dosing intervals across large chronic indications. Zumilokibart Zumilokibart is a long-acting antibody targeting IL-13 and is the company's lead program. Its extended...
On which exchange is APGE stock listed?
Apogee Therapeutics (APGE) is associated with NYSE, United States, Biopharma.
What is IL-13?
Zumilokibart Zumilokibart is a long-acting antibody targeting IL-13 and is the company's lead program.
Which conditions is Apogee Therapeutics targeting with IL-13?
Long-Acting I&I Biologics Apogee Therapeutics develops optimized biologics for inflammatory and immunologic diseases. Its candidates are engineered for differentiated efficacy and extended dosing intervals across large chronic indications. Zumilokibart Zumilokibart is a long-acting antibody targeting IL-13 and is the company's lead program. Its extended...
How does Apogee Therapeutics describe recent progress with IL-13?
Initiation of Phase 3 studies of zumilokibart in atopic dermatitis in 2026. Initiation of the ELEVATE Phase 2a study of zumilokibart in eosinophilic esophagitis in the second half of 2026. Interim data from the Phase 1b APG279 head-to-head study in atopic dermatitis in the second half of 2026. Initiation of the potentially registrational ASPIRE Phase 2b...
What is Long-Acting?
Long-Acting I&I Biologics Apogee Therapeutics develops optimized biologics for inflammatory and immunologic diseases.